FTC's Report Criticizing Drug Middlemen Is Flawed
Law 360
OCTOBER 3, 2024
The Federal Trade Commission's July report, which claims that pharmacy benefit managers are inflating drug costs, does not offer a credible analysis of PBMs, and its methodology lacks rigor, says Jay Ezrielev at Elevecon.
Let's personalize your content